Research programme: RNAi therapeutics - SomaGenics
Alternative Names: Short hairpin RNAs - SomaGenics; shRNAs - SomaGenics; sshRNA®Latest Information Update: 28 Feb 2025
Price :
$50 *
At a glance
- Originator SomaGenics
- Developer Arbutus Biopharma; Roche; SomaGenics
- Class Antivirals; Small interfering RNA
- Mechanism of Action RNA interference; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Diabetic foot ulcer; Hepatitis D
- Discontinued Hepatitis C
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Hepatitis-D in USA (Parenteral)
- 28 Feb 2025 No recent reports of development identified for research development in Diabetic-foot-ulcer in USA (Parenteral)
- 22 Feb 2023 Preclinical development is ongoing in USA for Hepatitis-D